Background: To evaluate the role and toxicity of ATRA therapy in newly-diagnosed APL patients aged > 60 yrs, the outcome of 16 consecutive elderly APL patients observed between January 1990 and June 1996 were analyzed.
Introduction
Acute promyelocytic leukemia (APL) is a well-characterized form of acute myeloid leukemia (AML) with distinctive biological and clinical features (severe hemorrhagic diathesis, the t(15;17) chromosome translocation) [1] [2] and a unique response in vitro and in vivo to the differentiating agent, all-trans retinoic acid (ATRA). In contrast to other AMLs, APL occurs most often in younger patients; it is less frequently observed in those aged > 60 years [3] .
Prior to the advent of ATRA, the use of intensive chemotherapy for newly diagnosed APL resulted in 70% complete remission (CR) and 25% three-year event-free survival (EFS) rates [4] . The introduction of ATRA and its combination with cytotoxic chemotherapy have made important contributions to improvement of the disease outcome by allowing a better control of the life-threatening coagulopathy and higher CR and EFS rates [5] [6] ,
No series specifically analyzing the subset of elderly APL patients has been reported to date, and little information is available on their prognostic outcome. However, the data pooled from the largest published trials show that these patients have a dismal outcome, similar to that of elderly patients with other AMLs.
We report herein our experience with 16 consecutive APL patients aged >60 who were treated at a single Institution with various schedules which included ATRA. The objective of the study was to evaluate the role and toxicity of this novel agent in the management of elderly patients with APL.
Patients and methods

Patients
From January 1990 to June 1996,64 newly diagnosed consecutive APL patients were observed at our Institution. Sixteen (25%) of them were aged > 60 years. Diagnosis was established according to the FrenchAmerican-British (FAB) guidelines and confirmed in all patients by molecular detection of the PML/RARa hybrid gene in leukemic cells. 2 /day) given on days 2, 4, 6 and 8. Patients in CR received three consolidation courses: patients in molecular CR after the consolidation were randomly allocated to receive one of four maintenance treatments for two years. Consolidation courses and maintenance treatments are described elsewhere [7] .
Evaluation of response
Hematological and molecular CR was defined as the presence of normal bone marrow cellularity with < 5% of leukemic promyelocytes, polymorphonuclear (PMN) cells > 1 x 10 9 /l and platelets (PLTS) > 100 x 10 9 /l without evidence of the RT-PCR-detectable PML/ RARa hybrid gene. Resistant disease was defined as persistence of > 5% leukemic promyelocytes after 90 days of ATRA.
Reverse transcriptase polymerase chain reaction (RT-PCR) analysis of the PML/RARa hybrid gene: The protocol and the oligoprimers used for RT-PCR of the PML-RARa hybrid gene have been reported elsewhere [8] .
Results
Patients' characteristics
The median age was 65.5 years (range 60-81), and the median leukocyte and PLTS counts were 1.7 x 10 9 /l (range 0.7-18.9) and 24 x 10 9 /l (range 10-302), respectively. All patients had the t(15;17) translocation and the PML/RARa chimeric transcript. Bleeding and/or laboratory evidence of a coagulopathy were present at diagnosis in all 16 patients.
With respect to previous or concomitant cardiovascular diseases, three patients had arterial hypertension requiring treatment, one had atrial fibrillation, one had had a myocardial infarction and two had suffered thrombotic episodes.
Response to induction treatment
By a median of 45 days (range 29-64 days) after the start of induction treatment 14 patients (87.5%) had achieved CR (Table 1) . Two patients (12.5%), both treated with ATRA alone, died of myocardial infarction (confirmed at autopsy in 1) after 18 and 22 days: both had hyperleukocytosis with no clear signs of ATRA syndrome.
With respect to induction toxicity, eight of 16 (50%) patients had fever >38°C, in five instances of undetermined origin, and sepsis was documented in three patients (one staphylococcus epidermidis, one pseudomonas aeruginosa and one Candida albicans sepsis).
ATRA syndrome was observed in two patients treated by the AIDA protocol, and both recovered rapidly after prompt administration of dexamethasone and discontinuation of ATRA.
Eight episodes of severe cardiovascular toxicity (WHO > 2) were observed in seven patients, three of whom had previously had cardiovascular disease, without signs of DIC (Table 2 ). In particular, four patients had myocardial infarction that was fatal in two; two patients had episodes of unstable angina and two had deep venous thrombosis (DVT) immediately following achievement of CR and discontinuation of ATRA.
Post-remission outcome and molecular follow-up
The patient in CR on ATRA alone was excluded from consolidation because of age > 80 years and was assigned a two-year maintenance treatment with metotrexate (MTX) + 6-mercaptopurine (6-MP): he relapsed 35 months after the first CR, and a second CR lasting seven months was achieved using ATRA alone.
The first of the two patients in CR after ATRA + MIDA was treated with a course of IDA + ara-C + 6TG and thereafter received a two-year MTX + 6-MP maintenance treatment; she is still in first CR after 63 months. The second patient received three monthly courses of IDA at low dosage (5 mg on day 1, 3, 5) and relapsed after 9 months of CR: he is still receiving a reinduction treatment with ATRA + IDA at low dosage.
Of the 11 patients in CR after AIDA, two were excluded from consolidation because of cardiovascular complications (myocardial infarction and myocardial infarction + DVT); they received MTX + 6-MP maintenance for two years and are still in CR after 16 and 38 months, respectively. Of the remaining nine patients, only three received the three consolidation courses with-out severe toxic effects: two of them started maintenance treatment, while the last patient withdrew from the therapy. They are still in CR after 11, 25 and 34 months, respectively.
The remaining six patients did not complete the consolidation phase. Two were excluded after the first consolidation course due to a broncopneumonia of fungal origin in one patient and a prolonged post-therapeutic aplasia >3 months in the other patient; the first patient started a two-year maintenance treatment with MTX + 6-MP alternated with ATRA, while the second patient declined further treatment. They are both in CR after eight and 14 months, respectively.
Four patients did not receive the third consolidation course due to disseminated fungal infection during cytopenia (2 patients) or cytopenia > 3 months following the second consolidation course (2 patients). The patients with disseminated fungal infection have discontinued treatment. The first died in CR of fungal infection after seven months, and the second relapsed after eight months and is still receiving reinduction treatment with ATRA alone. Of the remaining two patients, one started MTX + 6-MP maintenance and is still in CR after 33 months, while the second refused further treatment and relapsed 23 months after first CR, achieving a second CR with ATRA alone. The second CR has lasted 15 months and the RT-PCR for PML/RARa is thus far negative.
In summary, after a median follow-up after diagnosis of 19 months (range 7-64 months), the overall survival (OS) and EFS at 24 months are 81.2% and 58.3%, respectively. Hematological and molecular relapse occurred in only four of 14 patients; all nine of the patients still in first CR are RT-PCR-negative for PML/RARa, and five have been in CR >24 months (+25, +33, +34, +38, +63 months).
Discussion
Before the advent of ATRA, the prognosis of elderly APL patients was dismal, resembling that of elderly patients with other types of AML [4] . The introduction of ATRA has led to the rapid amelioration of APLassociated coagulopathy, and thereby rendered possible a better tolerance to chemotherapy. A recent study by the Japanese cooperative group reports a 76% CR rate with ATRA plus polychemotherapy in 17 patients aged >60 years [9] . Our CR rate of 87.5% confirms and improves on these results.
In the present series, no severe hemorrhagic complications were observed in any of the patients during induction despite the fact that in all of them there was laboratory evidence of coagulopathy at diagnosis. However, seven patients had important cardiovascular toxicity which involved thrombotic events in six cases (four myocardial infarctions and two DVT). An in vitro and in vivo thrombophilic effect of ATRA has been postulated [10] , although this is difficult to assess in the clinical setting.
It is worth noting that both of the episodes of DVT reported here occurred after achievement of the CR and ATRA discontinuation. Thus, pathogenetic mechanisms other than ATRA cannot be ruled out.
Cardiovascular toxicity was the cause of death in two patients receiving ATRA alone for induction; it was also the reason for exclusion from consolidation therapy of two additional patients treated by the AIDA protocol. Thus, only three of seven patients with cardiovascular toxicity were eligible for a consolidation program. In addition, only three of the nine patients who entered the consolidation phase in the AIDA protocol completed the three chemotherapy cycles. These data clearly indicate that elderly patients have low tolerance for intensive consolidation and that protocols adopted for these patients in future should include less aggressive post-remission chemotherapy as well as measures for prevention of thrombotic episodes during ATRA treatment.
In conclusion, despite the fact that the majority of patients in the present series received less treatment than younger APL patients, the two-year OS and EFS rates of 81.2% and 58.3% compare favourably with those observed in patients aged < 60 (85% and 69%, respectively), supporting a role for ATRA in achievement of these results.
